Skip to content
Open in App
Swedish Orphan Biovitrum AB logo

Swedish Orphan Biovitrum AB

web2

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of hae...

Symbol · 0MTD
Company profile

About

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company is in strategic partnership with Innate Pharma SA to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

GM

G. Mikael Dolsten

Independent Director

Company leadership profile.

IL

Iris Low-Friedrich

Independent Director

Company leadership profile.

DD

David D. Meek

Independent Chairman

Company leadership profile.

HW

Hans Wigzell

Chairman of Scientific Advisory Board

Company leadership profile.

FS

Filippa Stenberg

Independent Director

Company leadership profile.

RP

Ralf Pettersson

Member of Scientific Advisory Board

Company leadership profile.

SD

Stefan Del Prato

Member of Scientific Advisory Board

Company leadership profile.

SO

Stephen O'Rahilly

Member of Scientific Advisory Board

Company leadership profile.

JR

Jonathan Robert Sanders Arch

Member of Scientific Advisory Board

Company leadership profile.

KM

Katy Mazibuko

Employee Representative Director

Company leadership profile.

SS

Staffan Schuberg

Independent Director

Company leadership profile.

CB

Christophe Bourdon

Independent Director

Company leadership profile.

ML

Mats Lek

Employee Representative Director

Company leadership profile.

AH

Asa Hallert Riisberg

Director

Company leadership profile.

SR

Susanna Ronnback

Deputy Employee Representative Director

Company leadership profile.

SC

Sara Carlsson

Deputy Employee Representative Director

Company leadership profile.

Expert coverage

1 expert evaluated Swedish Orphan Biovitrum AB.

Orbitrum research

Experts evaluating Swedish Orphan Biovitrum AB

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment